386 related articles for article (PubMed ID: 15704045)
1. Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease.
Schoon EJ; Bollani S; Mills PR; Israeli E; Felsenberg D; Ljunghall S; Persson T; Haptén-White L; Graffner H; Bianchi Porro G; Vatn M; Stockbrügger RW;
Clin Gastroenterol Hepatol; 2005 Feb; 3(2):113-21. PubMed ID: 15704045
[TBL] [Abstract][Full Text] [Related]
2. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group.
Campieri M; Ferguson A; Doe W; Persson T; Nilsson LG
Gut; 1997 Aug; 41(2):209-14. PubMed ID: 9301500
[TBL] [Abstract][Full Text] [Related]
3. Budesonide versus prednisolone for the treatment of active Crohn's disease in children: a randomized, double-blind, controlled, multicentre trial.
Escher JC;
Eur J Gastroenterol Hepatol; 2004 Jan; 16(1):47-54. PubMed ID: 15095852
[TBL] [Abstract][Full Text] [Related]
4. A comparison of budesonide with prednisolone for active Crohn's disease.
Rutgeerts P; Löfberg R; Malchow H; Lamers C; Olaison G; Jewell D; Danielsson A; Goebell H; Thomsen OO; Lorenz-Meyer H
N Engl J Med; 1994 Sep; 331(13):842-5. PubMed ID: 8078530
[TBL] [Abstract][Full Text] [Related]
5. Budesonide (Entocort EC Capsules): a review of its therapeutic use in the management of active Crohn's disease in adults.
McKeage K; Goa KL
Drugs; 2002; 62(15):2263-82. PubMed ID: 12381231
[TBL] [Abstract][Full Text] [Related]
6. Budesonide for induction of remission in Crohn's disease.
Otley A; Steinhart AH
Cochrane Database Syst Rev; 2005 Oct; (4):CD000296. PubMed ID: 16235274
[TBL] [Abstract][Full Text] [Related]
7. Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease.
Cortot A; Colombel JF; Rutgeerts P; Lauritsen K; Malchow H; Hämling J; Winter T; Van Gossum A ; Persson T; Pettersson E
Gut; 2001 Feb; 48(2):186-90. PubMed ID: 11156638
[TBL] [Abstract][Full Text] [Related]
8. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group.
Greenberg GR; Feagan BG; Martin F; Sutherland LR; Thomson AB; Williams CN; Nilsson LG; Persson T
N Engl J Med; 1994 Sep; 331(13):836-41. PubMed ID: 8078529
[TBL] [Abstract][Full Text] [Related]
9. Effect of systemic corticosteroid therapy on risk for intra-abdominal or pelvic abscess in non-operated Crohn's disease.
Agrawal A; Durrani S; Leiper K; Ellis A; Morris AI; Rhodes JM
Clin Gastroenterol Hepatol; 2005 Dec; 3(12):1215-20. PubMed ID: 16361047
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease.
Feagan BG; Sandborn WJ; Baker JP; Cominelli F; Sutherland LR; Elson CO; Salzberg BA; Archambault A; Bernstein CN; Lichtenstein GR; Heath PK; Cameron S; Hanauer SB
Aliment Pharmacol Ther; 2005 Feb; 21(4):373-84. PubMed ID: 15709987
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of controlled-release budesonide in preserving bone mineral density in patients with Crohn's disease.
Abreu MT
Nat Clin Pract Gastroenterol Hepatol; 2005 May; 2(5):210-1. PubMed ID: 16265201
[No Abstract] [Full Text] [Related]
12. Randomized trial of etidronate plus calcium and vitamin D for treatment of low bone mineral density in Crohn's disease.
Siffledeen JS; Fedorak RN; Siminoski K; Jen H; Vaudan E; Abraham N; Steinhart H; Greenberg G
Clin Gastroenterol Hepatol; 2005 Feb; 3(2):122-32. PubMed ID: 15704046
[TBL] [Abstract][Full Text] [Related]
13. Replacement of conventional glucocorticoids by oral pH-modified release budesonide in active and inactive Crohn's disease: results of an open, prospective, multicenter trial.
Andus T; Gross V; Caesar I; Schulz HJ; Lochs H; Strohm WD; Gierend M; Weber A; Ewe K; Schölmerich J;
Dig Dis Sci; 2003 Feb; 48(2):373-8. PubMed ID: 12643618
[TBL] [Abstract][Full Text] [Related]
14. Budesonide in the treatment of Crohn's disease: a meta-analysis.
Papi C; Luchetti R; Gili L; Montanti S; Koch M; Capurso L
Aliment Pharmacol Ther; 2000 Nov; 14(11):1419-28. PubMed ID: 11069312
[TBL] [Abstract][Full Text] [Related]
15. Treatment of joint pain in Crohn's patients with budesonide controlled ileal release.
Florin TH; Graffner H; Nilsson LG; Persson T
Clin Exp Pharmacol Physiol; 2000 Apr; 27(4):295-8. PubMed ID: 10779128
[TBL] [Abstract][Full Text] [Related]
16. Maintenance of Crohn's disease over 12 months: fixed versus flexible dosing regimen using budesonide controlled ileal release capsules.
Green JR; Lobo AJ; Giaffer M; Travis S; Watkins HC;
Aliment Pharmacol Ther; 2001 Sep; 15(9):1331-41. PubMed ID: 11552903
[TBL] [Abstract][Full Text] [Related]
17. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.
Thomsen OO; Cortot A; Jewell D; Wright JP; Winter T; Veloso FT; Vatn M; Persson T; Pettersson E
N Engl J Med; 1998 Aug; 339(6):370-4. PubMed ID: 9691103
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of oral budesonide in Japanese patients with active Crohn's disease: a multicentre, double-blind, randomized, parallel-group Phase II study.
Suzuki Y; Motoya S; Takazoe M; Kosaka T; Date M; Nii M; Hibi T
J Crohns Colitis; 2013 Apr; 7(3):239-47. PubMed ID: 22766525
[TBL] [Abstract][Full Text] [Related]
19. Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group.
Greenberg GR; Feagan BG; Martin F; Sutherland LR; Thomson AB; Williams CN; Nilsson LG; Persson T
Gastroenterology; 1996 Jan; 110(1):45-51. PubMed ID: 8536887
[TBL] [Abstract][Full Text] [Related]
20. Budesonide in glucocorticoid dependent chronic active Crohn's disease; a pilot study.
Novacek G; Kleinberger M; Vogelsang H; Moser G; Lochs H
Z Gastroenterol; 1995 May; 33(5):251-4. PubMed ID: 7610692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
